Skip to main content
OpenTrials
Completed

NCT Number: NCT01540396

Gestational Diabetes Diagnostic Methods

This is a pilot feasibility study of 40 pregnant women to test the investigators' recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes. The two methods that are being compared are the 2 hour 75 gram OGGT (2011 ADA guidelines) versus a 1 hour 50 gram GCT + 3 hour 100 gram OGTT if the 1 hour result is abnormal (Carpenter and Coustan criteria).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States

About this study

This is a pilot feasibility study of 40 pregnant women between 24-28 weeks gestation to test the investigators recruitment, enrollment and randomization procedures in preparation to conduct a larger randomized control trial to compare diagnostic methods for gestational diabetes.

Forty women 18 years of age or older will be recruited at 20-24 weeks pregnancy from the ob/gyn outpatient practices at Magee-Women's hospital (MWH). Eligible women will return to MWH main lab between 24-28 weeks gestation for the routine 1 hour 50gm glucose challenge test. Women with blood glucose values less than 200 will be randomized to receive either the fasting 2 hour 75 gm oral glucose tolerance test (OGTT)or the 3 hour 100 gm OGGT within two weeks. Gestational diabetes will be determined for the 2 hour 75 gm OGGT arm based on the 2011 ADA guidelines and the 3 hour 100 gm OGGT arm based on the Carpenter and Coustan criteria. Patients and their providers will be informed of the diagnosis of gestational diabetes, but they will be blinded to the criteria used to make the diagnosis as well as the specific results of glucose tolerance testing.

Chart reviews will be conducted to assess for perinatal maternal and infant health factors (e.g.pregnancy weight, gestational weight gain, co morbidities) as well as for data on perinatal outcomes related to GDM such as macrosomia, c-sections, and birth trauma. Two brief self-administered questionnaire will assess participants' views on screening for gestational diabetes and assess participants experience with and solicit feedback on the study procedures.

At the end of this pilot study, the investigators will have experience with recruitment, retention, and randomization procedures and have made the necessary protocol revisions. If successful, this feasibility study will provide the preliminary data and feasibility justification needed to conduct a larger randomized control trial to compare the effectiveness of two diagnostic methods for gestational diabetes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton pregnancy
  • Plan to undergo gestational diabetes screening at 24-28 weeks' gestation.

Exclusion criteria

  • Existing Type 1 or Type 2 diabetes
  • Diabetes diagnosed early in pregnancy (less than 24 weeks gestation)
  • Multiple gestation (e.g. twins, triplets)
  • Chronic hypertension (requiring medications)
  • Oral, IM or IV corticosteroid use within the previous 30 days
  • Major congenital anomaly or anticipated preterm delivery before 28 weeks
  • Inability to complete 50 gram GCT before 28 completed weeks' gestation
  • Patients with known HIV, Hepatitis B or C virus.

Treatment and study plan

Dietary modification and medications

Behavioral

Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.

Primary outcomes

  1. Macrosomia

    Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

    Defined as birthweight >90th percentile for gestational age or birthweight >4000 grams

  2. Cesarean delivery

    Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

    Primary or repeat cesarean delivery

  3. Diagnosis of gestational diabetes

    Time frame: Will be followed from study enrollment until delivery (approximately 40 weeks' gestation)

    Assess how frequently a diagnosis of gestational diabetes is made

Secondary outcomes

  1. Pre-eclampsia or gestational hypertension

    Time frame: Will be assessed from study enrollment until 30 days after delivery

    New onset hypertension +/- proteinuria

  2. Neonatal hypoglycemia

    Time frame: First 24 hours of life

    Defined as blood glucose less than 80 mg/dL from heel stick within 1 hour after delivery

  3. Neonatal hyperbilirubinemia

    Time frame: First 7 days of life

    Defined as bilirubin greater than 5 mg/dL over 24 hours from heel stick

  4. Infant birth trauma

    Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

    Defined as shoulder dystocia/brachial plexus injuries

  5. Maternal birth trauma

    Time frame: Will be assessed from study enrollment until delivery (approximtaly 40 weeks' gestation)

    3rd or 4th degree perineal laceration or postpartum hemorrhage

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Registry information

Official study title

GD2M Study:Gestational Diabetes Diagnostic Methods

Acronym: GD2M

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
Feb 28, 2012
Registry last updated
Feb 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.